comscoreSABCS 2019: Five More Years of Femara Seems to Reduce Breast Cancer Recurrence Risk for Some Women

SABCS 2019: Five More Years of Femara Seems to Reduce Breast Cancer Recurrence Risk for Some Women

Dr. Terry Mamounas discusses the latest results from a study looking at whether an additional five years of Femara offers benefits.
Jan 10, 2020
00:00
Download
00:00

At the 2019 San Antonio Breast Cancer Symposium, Dr. Mamounas presented the latest results from a study looking at whether an additional 5 years of Femara after five years of a combination of tamoxifen and an aromatase inhibitor or 5 years of only an aromatase inhibitor offers benefits to postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.

Listen to the podcast to hear Dr. Mamounas discuss:

  • the results showing additional Femara reduced the risk of distant recurrence – the breast cancer coming back in a part of the body away from the breast

  • the amount of improvement in event-free survival

  • side effects associated with taking Femara for another 5 years

  • how he’s talking to his patients about these latest results

About the guest
 
Terry Mamounas, MD, MPH, FACS

Dr. Terry Mamounas is medical director of the comprehensive breast program at Orlando Health UF Health Cancer Center.

— Last updated on February 11, 2022, 7:58 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate